Registered title, quoted from ClinicalTrials.gov
A Dose REgimen-Finding Study of AGA2115 in Chinese Patients With Osteogenesis ImpeRfecta (EIR)
An open trial on osteogenesis imperfecta, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 5 hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 13 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 5
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
- Study siteChildren's Hospital of Soochow University苏州大学附属儿童医院SuzhouHospital page
- Study sitePeking Union Medical College Hospital北京协和医院BeijingHospital page
- Study siteSecond Xiangya Hospital中南大学湘雅二医院ChangshaHospital page
- Study siteShanghai Sixth People's Hospital上海市第六人民医院ShanghaiHospital page
- Study siteThe University of Hong Kong–Shenzhen Hospital香港大学深圳医院ShenzhenHospital page
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07557446, read on 13 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 3
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (3 points)Hide the checklist
12 years to 75 years; sex: all
Registered eligibility fields
Malignancy within the last 5 years.
Exclusion criterion 10
Pregnant or breastfeeding women, or women planning to become pregnant during the study or within 4 months after the last dose of IP.
Exclusion criterion 11
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; earlier treatment; day-to-day activity level; blood tests: counts, liver and kidney function; scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07557446, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Adults (18-75 years) or adolescents (12-17 years) with a confirmed diagnosis of Osteogenesis Imperfecta (OI) Type I, III, or IV with genetic confirmation of pathogenic variants in COL1A1 or COL1A2 genes
- BMD T-score of ≤-1.0 at the lumbar spine, total hip, or femoral neck (adults) or BMD Z-score of ≤-1.0 at the lumbar spine, total hip, or femoral neck (adolescents)
- Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol
Exclusion Criteria:
- Vitamin D deficiency
- Concomitant uncontrolled diseases or conditions that could affect bone metabolism such as hypo-/hyperparathyroidism, hypo-/hyperthyroidism, abnormal thyroid function or thyroid disease, or other endocrine disorders.
- Current hyper- or hypocalcemia.
- History of rickets, osteomalacia, or other significant skeletal disorders (excluding OI) leading to long-bone deformities and/or increased risk of fractures.
- Use of bisphosphonates within the past 6 months.
- Use of teriparatide, abaloparatide, strontium ranelate, or hormone replacement therapy within the past 12 months.
- Use of denosumab (or denosumab biosimilars) within the past 2 years.
- Use of anti-sclerostin antibody medications (romosozumab, setrusumab, blosozumab) at any time.
- History of myocardial infarction or stroke (or other cardiovascular associated event deemed significant) within the past 12 months.
- Malignancy within the last 5 years.
- Pregnant or breastfeeding women, or women planning to become pregnant during the study or within 4 months after the last dose of IP.
Quoted from ClinicalTrials.gov, NCT07557446, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07557446, read on 13 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.